search
Back to results

Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
INSULIN GLARGINE
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria :

  • 18 to 65 years old.
  • Type 2 diabetes patients insufficient controlled by 1-3 oral anti-hyperglycemic drugs (OADs) with stable dose at least 3 months:
  • If on 1 OAD, provided with the following doses (including but not limited to):

    • α-glucosidase inhibitor: 100mg, three times a day (tid);
    • metformin: 1.5-2.0 g/day;
    • sulphonylureas: sub-maximum (half dose above) to maximum tolerated dose;
    • thiazolidinediones: eg. pioglitazone, 30-40 mg/day.
    • Besides the medications listed above, if on 1 OAD, others should be maximum tolerated dose allowed in package insert.
  • If on 2-3 OADs, any range of dose is acceptable.
  • HbA1c >7%, and ≤10.5%.
  • FPG >7 mmol/L.
  • Body mass index (BMI) ≥20 kg/m^2, and ≤40 kg/m^2.
  • Diabetes duration ≥1 year.
  • Physician decides to and the patient is willing to start basal insulin (BI) treatment.
  • Willing to join the study and sign the informed consent.

Exclusion criteria:

  • Type 1 diabetes patients.
  • Patients with acute diabetic complications (including unexplained severe hypoglycemia in the last 6 months).
  • Previous treatment with insulin for more than 1 month cumulatively in last 1 year, or treatment with insulin in the last 3 months before the screening.
  • Known hypoglycemia unawareness or recurrent hypoglycemia.
  • Hypersensitivity to study drug or its excipients.
  • Any clinically significant acute major organ or systemic disease, or any other situation judged by the Investigator, that is difficult for the 24 weeks follow-up.
  • Pregnancy or breastfeeding women.
  • Have any mental disorders, lack self-control or not able to express accurately.
  • Involved in another clinical trial simultaneously or within a 1 month before start of trial.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sites / Locations

  • Investigational Site Number 156053
  • Investigational Site Number 156001
  • Investigational Site Number 156002
  • Investigational Site Number 156006
  • Investigational Site Number 156013
  • Investigational Site Number 156014
  • Investigational Site Number 156022
  • Investigational Site Number 156017
  • Investigational Site Number 156034
  • Investigational Site Number 156023
  • Investigational Site Number 156026
  • Investigational Site Number 156029
  • Investigational Site Number 156028
  • Investigational Site Number 156040
  • Investigational Site Number 156039
  • Investigational Site Number 156038
  • Investigational Site Number 156042
  • Investigational Site Number 156044
  • Investigational Site Number 156048
  • Investigational Site Number 156050
  • Investigational Site Number 156011
  • Investigational Site Number 156052
  • Investigational Site Number 156016
  • Investigational Site Number 156041
  • Investigational Site Number 156020
  • Investigational Site Number 156018
  • Investigational Site Number 156019
  • Investigational Site Number 156031
  • Investigational Site Number 156043
  • Investigational Site Number 156049
  • Investigational Site Number 156035
  • Investigational Site Number 156036
  • Investigational Site Number 156047
  • Investigational Site Number 156027
  • Investigational Site Number 156015
  • Investigational Site Number 156054
  • Investigational Site Number 156007
  • Investigational Site Number 156010
  • Investigational Site Number 156055
  • Investigational Site Number 156037
  • Investigational Site Number 156033
  • Investigational Site Number 156030
  • Investigational Site Number 156032
  • Investigational Site Number 156025

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Group 1

Group 2

Group 3

Arm Description

Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=5.6 mmol/L

Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=6.1 mmol/L

Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=7.0 mmol/L

Outcomes

Primary Outcome Measures

Percentage of patients with HbA1c <7% achievement

Secondary Outcome Measures

Percentage of patients achieving HbA1c <=6.5%
Percentage of patients achieving FPG target with HbA1c <7%
Percentage of patients achieving HbA1c <7% without hypoglycemia
Percentage of patients achieving the FPG target without hypoglycemia
Percentage of patients achieving FPG target
Percentage of patients achieving PPG target (2-hour post-breakfast <10 mmol/L)
Change from baseline in HbA1c
Change in FPG
Change in PPG
Change in insulin doses in each arm
Change in body weight in each treatment arm
Percentage of patients experienced hypoglycemic events

Full Information

First Posted
September 8, 2015
Last Updated
April 21, 2022
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT02545842
Brief Title
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
Official Title
Titration Target for Chinese Type 2 Diabetes Mellitus Patients Using Insulin Glargine to Achieve Glycaemic Goals: An Assessment of Three Different Fasting Plasma Glucose Targets - BEYOND III/FPG GOAL Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
September 7, 2015 (undefined)
Primary Completion Date
April 20, 2018 (Actual)
Study Completion Date
April 20, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary Objective: To identify a best fasting plasma glucose (FPG) target for Chinese type 2 diabetes patients using insulin glargine which can provide the highest control rate of glycated hemoglobin (HbA1c) < 7%. Secondary Objectives: The control rate of HbA1c ≤6.5% achievement. The control rate of HbA1c <7.0% in patients achieving their FPG target. The percentage of HbA1c <7% without hypoglycemia. The percentage of patients achieving the FPG target without hypoglycemia. The percentage of patients achieving the FPG target and post prandial glucose (PPG) target (2-hour post breakfast <10 mmol/L).
Detailed Description
The study duration for each patient will be 27 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
947 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1
Arm Type
Experimental
Arm Description
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=5.6 mmol/L
Arm Title
Group 2
Arm Type
Experimental
Arm Description
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=6.1 mmol/L
Arm Title
Group 3
Arm Type
Experimental
Arm Description
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=7.0 mmol/L
Intervention Type
Drug
Intervention Name(s)
INSULIN GLARGINE
Other Intervention Name(s)
HOE901
Intervention Description
Pharmaceutical form: solution Route of administration: subcutaneous
Primary Outcome Measure Information:
Title
Percentage of patients with HbA1c <7% achievement
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Percentage of patients achieving HbA1c <=6.5%
Time Frame
24 weeks
Title
Percentage of patients achieving FPG target with HbA1c <7%
Time Frame
24 weeks
Title
Percentage of patients achieving HbA1c <7% without hypoglycemia
Time Frame
24 weeks
Title
Percentage of patients achieving the FPG target without hypoglycemia
Time Frame
24 weeks
Title
Percentage of patients achieving FPG target
Time Frame
24 weeks
Title
Percentage of patients achieving PPG target (2-hour post-breakfast <10 mmol/L)
Time Frame
24 weeks
Title
Change from baseline in HbA1c
Time Frame
Baseline to 24 weeks
Title
Change in FPG
Time Frame
8 weeks to 24 weeks
Title
Change in PPG
Time Frame
Baseline to 24 weeks
Title
Change in insulin doses in each arm
Time Frame
1 week to 24 weeks
Title
Change in body weight in each treatment arm
Time Frame
Baseline to 24 weeks
Title
Percentage of patients experienced hypoglycemic events
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria : 18 to 65 years old. Type 2 diabetes patients insufficient controlled by 1-3 oral anti-hyperglycemic drugs (OADs) with stable dose at least 3 months: If on 1 OAD, provided with the following doses (including but not limited to): α-glucosidase inhibitor: 100mg, three times a day (tid); metformin: 1.5-2.0 g/day; sulphonylureas: sub-maximum (half dose above) to maximum tolerated dose; thiazolidinediones: eg. pioglitazone, 30-40 mg/day. Besides the medications listed above, if on 1 OAD, others should be maximum tolerated dose allowed in package insert. If on 2-3 OADs, any range of dose is acceptable. HbA1c >7%, and ≤10.5%. FPG >7 mmol/L. Body mass index (BMI) ≥20 kg/m^2, and ≤40 kg/m^2. Diabetes duration ≥1 year. Physician decides to and the patient is willing to start basal insulin (BI) treatment. Willing to join the study and sign the informed consent. Exclusion criteria: Type 1 diabetes patients. Patients with acute diabetic complications (including unexplained severe hypoglycemia in the last 6 months). Previous treatment with insulin for more than 1 month cumulatively in last 1 year, or treatment with insulin in the last 3 months before the screening. Known hypoglycemia unawareness or recurrent hypoglycemia. Hypersensitivity to study drug or its excipients. Any clinically significant acute major organ or systemic disease, or any other situation judged by the Investigator, that is difficult for the 24 weeks follow-up. Pregnancy or breastfeeding women. Have any mental disorders, lack self-control or not able to express accurately. Involved in another clinical trial simultaneously or within a 1 month before start of trial. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Investigational Site Number 156053
City
Anshan
Country
China
Facility Name
Investigational Site Number 156001
City
Beijing
Country
China
Facility Name
Investigational Site Number 156002
City
Beijing
Country
China
Facility Name
Investigational Site Number 156006
City
Beijing
Country
China
Facility Name
Investigational Site Number 156013
City
Changchun
ZIP/Postal Code
130033
Country
China
Facility Name
Investigational Site Number 156014
City
Changchun
ZIP/Postal Code
130033
Country
China
Facility Name
Investigational Site Number 156022
City
Changde
ZIP/Postal Code
415000
Country
China
Facility Name
Investigational Site Number 156017
City
Changsha
Country
China
Facility Name
Investigational Site Number 156034
City
Changzhou
Country
China
Facility Name
Investigational Site Number 156023
City
Chenzhou
Country
China
Facility Name
Investigational Site Number 156026
City
Guangzhou
ZIP/Postal Code
510515
Country
China
Facility Name
Investigational Site Number 156029
City
Haikou
ZIP/Postal Code
570102
Country
China
Facility Name
Investigational Site Number 156028
City
Haikou
Country
China
Facility Name
Investigational Site Number 156040
City
Haikou
Country
China
Facility Name
Investigational Site Number 156039
City
Hangzhou
ZIP/Postal Code
310013
Country
China
Facility Name
Investigational Site Number 156038
City
Hangzhou
Country
China
Facility Name
Investigational Site Number 156042
City
Hangzhou
Country
China
Facility Name
Investigational Site Number 156044
City
Hangzhou
Country
China
Facility Name
Investigational Site Number 156048
City
Hefei
Country
China
Facility Name
Investigational Site Number 156050
City
Hefei
Country
China
Facility Name
Investigational Site Number 156011
City
Kunming
Country
China
Facility Name
Investigational Site Number 156052
City
Kunming
Country
China
Facility Name
Investigational Site Number 156016
City
Lanzhou
Country
China
Facility Name
Investigational Site Number 156041
City
Lishui
Country
China
Facility Name
Investigational Site Number 156020
City
Nanchang
ZIP/Postal Code
330006
Country
China
Facility Name
Investigational Site Number 156018
City
Nanchang
Country
China
Facility Name
Investigational Site Number 156019
City
Nanchang
Country
China
Facility Name
Investigational Site Number 156031
City
Nanjing
Country
China
Facility Name
Investigational Site Number 156043
City
Nanjing
Country
China
Facility Name
Investigational Site Number 156049
City
Nanjing
Country
China
Facility Name
Investigational Site Number 156035
City
Shanghai
Country
China
Facility Name
Investigational Site Number 156036
City
Shanghai
Country
China
Facility Name
Investigational Site Number 156047
City
Shanghai
Country
China
Facility Name
Investigational Site Number 156027
City
Shantou
Country
China
Facility Name
Investigational Site Number 156015
City
Shenyang
Country
China
Facility Name
Investigational Site Number 156054
City
Shijiazhuang
Country
China
Facility Name
Investigational Site Number 156007
City
Tangshan
ZIP/Postal Code
063000
Country
China
Facility Name
Investigational Site Number 156010
City
Tianjin
ZIP/Postal Code
300032
Country
China
Facility Name
Investigational Site Number 156055
City
Wuhan
ZIP/Postal Code
430000
Country
China
Facility Name
Investigational Site Number 156037
City
Xuzhou
Country
China
Facility Name
Investigational Site Number 156033
City
Yangzhou
Country
China
Facility Name
Investigational Site Number 156030
City
Yueyang
Country
China
Facility Name
Investigational Site Number 156032
City
Zhenjiang
ZIP/Postal Code
212001
Country
China
Facility Name
Investigational Site Number 156025
City
Zhuzhou
ZIP/Postal Code
412000
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Citations:
PubMed Identifier
35430674
Citation
Wang X, Wu G, Shen D, Zhang X, Yang W. Unmet Needs of Glycaemic Control and Risk Factors of Residual Hyperglycaemia in a Chinese Population with Type 2 Diabetes Initiating Basal Insulin: A Post Hoc Analysis of the FPG GOAL Study. Adv Ther. 2022 Jun;39(6):2820-2830. doi: 10.1007/s12325-022-02128-y. Epub 2022 Apr 16.
Results Reference
derived
PubMed Identifier
34757600
Citation
Li L, Yang T, Xue Y, Ruan P, Du J, Li Y, Zhang X, Cui N, Yang W. Influence of Fasting Plasma Glucose Targets on Glycemic Variability in Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of the FPG GOAL Trial (BEYOND III). Adv Ther. 2022 Jan;39(1):421-429. doi: 10.1007/s12325-021-01932-2. Epub 2021 Nov 10.
Results Reference
derived
PubMed Identifier
32671687
Citation
Ma J, Lei M, Li Y, Zhang X, Cui N, Yang W. Influence of Fasting Glucose Levels on Achieving Glycemic Target in Individuals with Type 2 Diabetes: a Post Hoc Analysis. Adv Ther. 2020 Sep;37(9):3816-3826. doi: 10.1007/s12325-020-01410-1. Epub 2020 Jul 15.
Results Reference
derived
PubMed Identifier
27669747
Citation
Yang W, Yang Z, Zhao J, Lu H, Luo T. Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial. Trials. 2016 Sep 26;17(1):470. doi: 10.1186/s13063-016-1588-6.
Results Reference
derived

Learn more about this trial

Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)

We'll reach out to this number within 24 hrs